VG 202
Alternative Names: VG-202Latest Information Update: 04 Feb 2021
At a glance
- Originator Virogin Biotech
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin 15 receptor alpha expression stimulants; Interleukin-12 expression stimulants; Interleukin-15 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 18 Jan 2021 VG 202 is available for licensing as of 18 Jan 2021. https://virogin.com/
- 18 Jan 2021 Preclinical trials in Liver cancer in Canada (Intratumoural) (Virogin Biotech pipeline, January 2021)